Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 3698 Haven Ave, Redwood City,california 94063,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Redwood City, California
Multitude Therapeutics Questions
Multitude Therapeutics's website is https://www.multitudetherapeutics.info
Multitude Therapeutics's LinkedIn profile is https://www.linkedin.com/company/multitude-therapeutics
Multitude Therapeutics has
7 employees.
View email and phone details for 7
employees at Multitude Therapeutics.
Multitude Therapeutics's industry is
Biotechnology Research
Multitude Therapeutics's top competitors are
Lepu Biopharma Co., Ltd,
Precision Biologics, Inc.,
Ambrx,
Medilink Therapeutics,
Tavotek Biotherapeutics,
Solve Therapeutics, Inc.,
Irbm,
Adcendo,
Lanova Medicines,
Foreseen Biotechnology.
Multitude Therapeutics's categories are Biotechnology Research
Multitude Therapeutics's founding year is 2018
